PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis (Q26992267)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis	scientific article

Statements

scholarly article

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis (English)

1 reference

0 references

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

C. Mao

1

1 reference

Z. Y. Yang

2

1 reference

X. F. Hu

3

1 reference

Q. Chen

4

1 reference

J. L. Tang

5

1 reference

language of work or name

1 reference

publication date

June 2012

1 reference

Annals of Oncology

1 reference

23

1 reference

1518-25

1 reference

6

1 reference

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Misleading funnel plot for detection of bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Testing for qualitative interactions between treatment effects and patient subsets.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR464

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26992267&oldid=1953199302"